Skip to main content

ChanTest Wins $5M Ohio Grant

NEW YORK (GenomeWeb News) – ChanTest has won a $4.8 million grant from the State of Ohio that it plans to use to expand its G-protein coupled receptor and ion channel products and services, the company said today.

The Cleveland-based company received the competitive grant through Ohio's Third Frontier Research and Commercialization Program

The company plans to use the funds to expand its library of validated ion channel and GPCR cell line products and services, and on its electrogenic transporter and stem-cell derived heart cell services.

The company said that its cell lines and related products cover "nearly half the known drugable genome," and its services include scale-up and cryopreservation of cells for high-throughput screening, and cell line construction.

The company received an Ohio Third Frontier grant in 2006, which it used to develop its technology, ChanTest CEO Arthur Brown said in a statement.

"This new funding will help us develop additional drug discovery and development research services, ion channel and GPCR cell lines, and membrane products to help our biotech and pharmaceutical customers create better, safer drugs," Brown said.

The company said that Analiza, another Cleveland company, will provide analytical chemistry to support the ChanTest.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.